Feature

Jade Corporate Presentation

Jade Biosciences is focused on developing innovative, best-in-class therapies to address critical unmet needs in autoimmune diseases.

Our lead program, JADE-001, targets the anti-APRIL (A Proliferation-Inducing Ligand) pathway for the treatment of immunoglobin A nephropathy (IgAN), a chronic kidney disease that can impair kidney function over time. JADE-001 aims to reduce harmful IgA antibodies, lower proteinuria (a key marker of kidney damage), and preserve long-term kidney function. A first-in-human clinical trial is expected to begin in the second half of 2025, with initial data anticipated in early 2026.

In addition to JADE-001, our pipeline includes JADE-002 and JADE-003, two preclinical antibody programs targeting undisclosed pathways. See our pipeline to learn more.

Events &
Presenations